These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 6131493)

  • 1. Anatomical and biochemical basis of the extrapyramidal disorders.
    Gauthier S; Sourkes TL
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):595-9. PubMed ID: 6131493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal calcium channel antagonist receptors in Huntington's disease and Parkinson's disease.
    Watson DL; Carpenter CL; Marks SS; Greenberg DA
    Ann Neurol; 1988 Mar; 23(3):303-5. PubMed ID: 2967667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Huntington's chorea and cerebellar atrophy. Apropos of amanatomo-clinical case].
    Castaigne P; Escourolle R; Gray MF
    Rev Neurol (Paris); 1976 Apr; 132(4):233-40. PubMed ID: 132690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The basal ganglia in extrapyramidal dysfunction.
    Barnes CD
    Brain Res Bull; 1983 Aug; 11(2):271-5. PubMed ID: 6226339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
    Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
    Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interhemispheric connections of the striatum: Implications for Parkinson's disease and drug-induced dyskinesias.
    Lieu CA; Subramanian T
    Brain Res Bull; 2012 Jan; 87(1):1-9. PubMed ID: 21963946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI and SPECT of midbrain and striatal degeneration in fragile X-associated tremor/ataxia syndrome.
    Scaglione C; Ginestroni A; Vella A; Dotti MT; Nave RD; Rizzo G; De Cristofaro MT; De Stefano N; Piacentini S; Martinelli P; Mascalchi M
    J Neurol; 2008 Jan; 255(1):144-6. PubMed ID: 18080849
    [No Abstract]   [Full Text] [Related]  

  • 9. Neurochemical anatomy of movement disorders.
    Young AB; Penney JB
    Neurol Clin; 1984 Aug; 2(3):417-33. PubMed ID: 6152481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rare extrapyramidal disorders: progressive supranuclear paralysis and striato-nigral degeneration].
    Marttila R; Kalimo H; Nikoskelainen E; Rinne UK
    Duodecim; 1982; 98(3):191-200. PubMed ID: 7060514
    [No Abstract]   [Full Text] [Related]  

  • 11. Anatomy and pathology of extrapyramidal diseases.
    Seab JA
    Brain Res Bull; 1983 Aug; 11(2):135-41. PubMed ID: 6226338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.
    Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP
    Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Type of familial extrapyramidal disease--cortico-striato-pallido-nigral degeneration (author's transl)].
    Maeda S; Yokoi S; Isaka K; Numabe T
    Seishin Shinkeigaku Zasshi; 1973 Oct; 75(10):657-72. PubMed ID: 4798818
    [No Abstract]   [Full Text] [Related]  

  • 15. Microtopography of D1 dopaminergic binding sites in the human substantia nigra: an autoradiographic study.
    Thibaut F; Hirsch EC; Raisman R; Javoy-Agid F; Agid Y
    Neuroscience; 1990; 37(2):387-98. PubMed ID: 1983469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
    Bernheimer H; Birkmayer W; Hornykiewicz O; Jellinger K; Seitelberger F
    J Neurol Sci; 1973 Dec; 20(4):415-55. PubMed ID: 4272516
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuropathology of Parkinson's disease and related syndromes.
    Gibb WR
    Neurol Clin; 1992 May; 10(2):361-76. PubMed ID: 1584179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
    Chinaglia G; Alvarez FJ; Probst A; Palacios JM
    Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry].
    Bartholini G
    Schweiz Arch Neurol Neurochir Psychiatr; 1979; 125(2):265-9. PubMed ID: 45343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin in human brain and its relation to extrapyramidal system. Immunohistochemical study on postmortem human brains.
    Goto S; Matsukado Y; Mihara Y; Inoue N; Miyamoto E
    Acta Neuropathol; 1986; 72(2):150-6. PubMed ID: 2950715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.